pH-enzyme responsive liposomes represent a cutting-edge drug delivery system, effectively utilizing dual stimuli to precisely control the release of therapeutic agents in response to specific pH levels and enzymatic activity. CD Formulation supports the development of high-performance liposomes that respond to pH and enzymes using advanced technology.
Enzyme-sensitive release systems typically rely on elevated enzyme expression levels to catalyze biochemical transformations that trigger drug release within a specific tumor microenvironment. These enzymes can also serve as biomarkers for diagnosing or prognosticating tumor stage. In a pH- and enzyme-double-responsive liposome delivery system, cargo can be released upon demand, either through exposure to acidic environments (such as those found in tumor cells and inflammatory tissues) or via selective enzyme binding.
Fig.1 Schematic of the structure of pH/enzyme dual stimuli-sensitive nanoparticles. (Karimi, Mahdi, et al., 2015)
By investigating pH and enzyme-triggered mechanisms, we support our clients in developing innovative dual-responsive liposomes, providing fresh perspectives and strategic approaches.
Lipids, as a crucial component influencing the bilayer structure of liposomes, can serve as pivotal regulators of stimulus-response. Through this service, we help clients develop enzymatically cleavable lipids (PEG-MMP-2-lipid) or pH-sensitive lipid varieties.
The service focuses on coordinating the regulation of liposomes by utilizing polymer-containing liposomes and enzymes to induce enzyme-triggered conformational changes, thereby facilitating the release of the liposomal contents, e.g. P(NIPAM-co-MAA-co-ODA)and glucose oxidase.
We divided the study of enzyme response mechanism into extracellular enzymes and intracellular enzymes, including matrix metalloproteinase, urokinase-type plasminogen activator, elastase, prostate-specific antigen (PSA), intracellular enzymes, and other enzymes.
We offer a range of analyses for custom liposome products such as physical and chemical properties, in vivo, and in vitro analyses.
Techniques and Platforms | Specifics |
pH-enzyme Responsive Development Platform |
|
Product Application Platform |
|
Characterization Platform |
|
Technology: PD-L1 inhibitor conjugate polymer-liposomes technique
Journal: Biomacromolecules
IF: 6.0
Published: 2019
Results: Here, the authors constructed liposomes with a matrix metalloproteinase (MMPs) reactive portion and PD-L1 inhibitor conjugate, combined with low-dose chemotherapy, to achieve enhanced antitumor efficacy. After introducing the pH-responsive polymer into the polymer-liposomes (LPDp), the co-assembly is almost stable under physiological conditions and in the tumor microenvironment and releases the loaded material on the lysosome. Compared to free PD-L1 inhibitors, LPDp improves the biological distribution and on-demand release of peptide inhibitors in tumor areas.
Fig.2 Schematic representation of tumor microenvironment pH/enzyme dual-responsive polymer-liposomes. (Liu, Ya, et al., 2023)
With state-of-the-art technology and platforms, CD Formulation strives to deliver the most intelligent pH/enzyme dual-responsive liposomes. If you require any assistance, please do not hesitate to contact us.
References